{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:26:13Z","timestamp":1783603573306,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40261-017-0555-7","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T12:28:13Z","timestamp":1500467293000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents"],"prefix":"10.1007","volume":"37","author":[{"given":"Mehmet Fatih","family":"Ceylan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00fcl","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Tural Hesapcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Cop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"555_CR1","first-page":"754","volume-title":"Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook","author":"L Scahill","year":"2007","unstructured":"Scahill L, Oesterheld JR, Martin A. General principles, specific drug treatments, and clinical practice. In: Martin A, Volkmar FR, editors. Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 754\u201388.","edition":"4"},{"key":"555_CR2","volume-title":"The American psychiatric publishing textbook of psychopharmacology","author":"AF Schatzberg","year":"2009","unstructured":"Schatzberg AF, Nemeroff CB. The American psychiatric publishing textbook of psychopharmacology. 4th ed. Washington DC: American Psychiatric Pub; 2009.","edition":"4"},{"key":"555_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341.","journal-title":"Lancet."},{"key":"555_CR4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/NDT.S3311","volume":"4","author":"MK Rainer","year":"2008","unstructured":"Rainer MK. Risperidone long-acting injection: a review of its long-term safety and efficacy. Neuropsychiatr Dis Treat. 2008;4:919\u201327.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"555_CR5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-5618.2010.00850.x","volume":"12","author":"MN Pavuluri","year":"2010","unstructured":"Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, et al. Double-blind randomized trial of risperidone vs. divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12:593\u2013605.","journal-title":"Bipolar Disord."},{"key":"555_CR6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2004.05.017","volume":"1","author":"MN Pavuluri","year":"2004","unstructured":"Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;1:103\u201311.","journal-title":"J Affect Disord."},{"key":"555_CR7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with\u00a0autistic and other pervasive developmental disorders. Pediatrics. 2004;114:634\u201341.","journal-title":"Pediatrics."},{"key":"555_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/070674371506000204","volume":"60","author":"DA Gorman","year":"2015","unstructured":"Gorman DA, Gardner DM, Murphy AL, Feldman M, B\u00e9langer SA, Steele MM, Boylan K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60:62\u201376.","journal-title":"Can J Psychiatry."},{"key":"555_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejpn.2011.12.001","volume":"16","author":"H Rickards","year":"2012","unstructured":"Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol. 2012;16:361\u20134.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"555_CR10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.08l04487","volume":"70","author":"L Fu-I","year":"2009","unstructured":"Fu-I L, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry. 2009;70(4):604\u20136.","journal-title":"J Clin Psychiatry."},{"key":"555_CR11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/cap.2015.0091","volume":"26","author":"S Pope","year":"2016","unstructured":"Pope S, Zaraa SG. Efficacy of\u00a0long-acting injectable\u00a0antipsychotics in adolescents. J Child Adolesc Psychopharmacol. 2016;26:391\u20134.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"555_CR12","first-page":"3","volume":"15","author":"MA Boarati","year":"2013","unstructured":"Boarati MA, Wang YP, Ferreira-Maia AP, Cavalcanti AR, Fu-I L. Six-month open-label follow-up of\u00a0risperidone\u00a0long-acting\u00a0injection use in pediatric bipolar disorder. Prim Care Companion CNS Disord. 2013;15:3.","journal-title":"Prim Care Companion CNS Disord."},{"key":"555_CR13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","volume":"36","author":"J Kaufman","year":"1997","unstructured":"Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"555_CR14","volume-title":"WISC-R manual for the wechsler intelligence scale for children-revised","author":"D Wechsler","year":"1974","unstructured":"Wechsler D. WISC-R manual for the wechsler intelligence scale for children-revised. New York: Psychological Corporation; 1974."},{"key":"555_CR15","volume-title":"Assessing adolescent and adult intelligence","author":"AS Kaufman","year":"2006","unstructured":"Kaufman AS, Lichtenberger E. Assessing adolescent and adult intelligence. 3rd ed. Hoboken: Wiley; 2006.","edition":"3"},{"key":"555_CR16","first-page":"109","volume":"11","author":"B Gokler","year":"2004","unstructured":"Gokler B, Unal F, Pehlivanturk B, Kultur EC, Akdemir D, Taner Y. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version\u2014the validity and reliability of adaptation in Turkish. \u00c7ocukve Gen\u00e7lik Ruh Sagl\u0131g\u0131 Dergisi. 2004;11:109\u201316.","journal-title":"\u00c7ocukve Gen\u00e7lik Ruh Sagl\u0131g\u0131 Dergisi."},{"key":"555_CR17","volume-title":"Wechsler Cocuklar\u0130cinZekaOlce\u011fi (WISCR) El Kitab\u0131","author":"I Sava\u015f\u0131r","year":"1995","unstructured":"Sava\u015f\u0131r I, \u015eahin N. Wechsler Cocuklar\u0130cinZekaOlce\u011fi (WISCR) El Kitab\u0131. Ankara: Turk PsikologlarDerne\u011fiYay\u0131nlar\u0131; 1995."},{"key":"555_CR18","unstructured":"Guy W: Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76\u2013338. National Institute of Mental Health, Rockville, MD. 1976; 218\u2013222."},{"key":"555_CR19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","volume":"166","author":"JC Day","year":"1995","unstructured":"Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650\u20133.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"555_CR20","first-page":"147","volume":"16","author":"S Yilmaz","year":"2006","unstructured":"Yilmaz S, Buzlu S. Liverpool \u00dcniversitesi Antipsikotiklerin Yan Etkilerini De\u011ferlendirme \u00d6l\u00e7e\u011fi\u2019nin T\u00fcrk\u00e7e Formunun G\u00fcvenilirli\u011fi. Klinik Psikofarmakoloji B\u00fclteni. 2006;16(3):147\u201354.","journal-title":"Klinik Psikofarmakoloji B\u00fclteni."},{"key":"555_CR21","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","volume":"41","author":"R Snyder","year":"2002","unstructured":"Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Risperidone conduct study group: effects of\u00a0risperidone\u00a0on conduct and\u00a0disruptive\u00a0behavior\u00a0disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026\u201336.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"555_CR22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","volume":"39","author":"RL Findling","year":"2000","unstructured":"Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509\u201316.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"555_CR23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","volume":"44","author":"J Croonenberghs","year":"2005","unstructured":"Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van DS. Risperidone disruptive behavior study group. Risperidone in children with disruptive behavior disorders and sub-average intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005;44:64\u201372.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"555_CR24","first-page":"454","volume-title":"Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook","author":"JM Rey","year":"2007","unstructured":"Rey JM, Walter G, Soutullo CA. Oppositional defiant and conduct disorders. In: Martin A, Volkmar FR, editors. Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 454\u201366.","edition":"4"},{"key":"555_CR25","first-page":"467","volume-title":"Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook","author":"JS Blader","year":"2007","unstructured":"Blader JS, Jensen PS. Aggression in children: an integrative approach. In: Martin A, Volkmar FR, editors. Lewis\u2019 child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 467\u201383.","edition":"4"},{"key":"555_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2016.03.043","volume":"197","author":"CS Wu","year":"2016","unstructured":"Wu CS, Hsieh MH, Tang CH, Chang CJ. Comparative\u00a0effectiveness of\u00a0long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. J Affect Disord. 2016;197:189\u201395.","journal-title":"J Affect Disord."},{"key":"555_CR27","doi-asserted-by":"crossref","first-page":"e9290","DOI":"10.1192\/bjp.179.4.290","volume":"179","author":"CE Adams","year":"2001","unstructured":"Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:e9290.","journal-title":"Br J Psychiatry"},{"key":"555_CR28","first-page":"266","volume":"5","author":"P Chue","year":"2005","unstructured":"Chue P, Llorca P, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res. 2005;5:266\u201374.","journal-title":"J Appl Res."},{"key":"555_CR29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3111\/13696990701646825","volume":"10","author":"L Beauclair","year":"2007","unstructured":"Beauclair L, Chue P, McCormic J, Camacho F, Lam A, Luong D. Impact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophrenia. J Med Econ. 2007;10:427\u201342.","journal-title":"J Med Econ"},{"key":"555_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","volume":"28","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli P, Kempton MJ, Rosenheck RA. Effcacy and safetyof second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:57\u201366.","journal-title":"Int Clin Psychopharmacol"},{"key":"555_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900026304","volume":"12","author":"JM Kane","year":"2007","unstructured":"Kane JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007;12:21\u20136.","journal-title":"CNS Spectr"},{"key":"555_CR32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1192\/bjp.184.6.509","volume":"184","author":"M Knapp","year":"2004","unstructured":"Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatr. 2004;184:509\u201316.","journal-title":"Br. J. Psychiatr."},{"issue":"4","key":"555_CR33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000353","volume":"35","author":"JA Doshi","year":"2015","unstructured":"Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent oral\u00a0antipsychotic\u00a0drug use among schizophrenia patients initiated on\u00a0long-actingInjectable\u00a0antipsychotics\u00a0post-hospital discharge. J Clin Psychopharmacol. 2015;35(4):442\u20136.","journal-title":"J Clin Psychopharmacol."},{"key":"555_CR34","first-page":"12","volume":"26","author":"T Lambert","year":"2012","unstructured":"Lambert T, Emmerson B, Hustig H, Resseler S, Jacobs A, Butcher B. e-STAR Research Group. Long-acting\u00a0risperidone\u00a0in\u00a0Australian\u00a0patients\u00a0with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry. 2012;26:12\u201325.","journal-title":"BMC Psychiatry."},{"key":"555_CR35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4088\/JCP.0908e26","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69:26\u201336.","journal-title":"J Clin Psychiatry."},{"key":"555_CR36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","volume":"21","author":"A Zuddas","year":"2011","unstructured":"Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600\u201320.","journal-title":"Eur Neuropsychopharmacol."},{"key":"555_CR37","unstructured":"Morselli PL, Pippenger CE. Drug disposition during development: an overview.\u00a0In:\u00a0Fundamentals.\u00a0Applied Therapeutic Drug Monitoring.\u00a0Vol 1.\u00a02nd edition.\u00a0The American Association for Clinical Chemistry, Washington DC. 1982; 63\u201370."},{"key":"555_CR38","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125\u201332.","journal-title":"Am J Psychiatry."},{"key":"555_CR39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/cap.2012.0058","volume":"23","author":"JM Kent","year":"2013","unstructured":"Kent JM, Hough D, Singh J, Karcher K, Pandina G. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2013;23:676\u201386.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"555_CR40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical antipsychotic trials of intervention effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med."},{"key":"555_CR41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in\u00a0children\u00a0and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32:309\u201316.","journal-title":"J Clin Psychopharmacol."},{"key":"555_CR42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","volume":"31","author":"AM Lostia","year":"2009","unstructured":"Lostia AM, Mazzarini L, Pacchiarotti I, Lionetto L, De Rossi P, Sanna L, Sani G, Kotzalidis GD, Girardi P, Simmaco M, Tatarelli R. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit. 2009;31:475\u201381.","journal-title":"Ther Drug Monit."},{"key":"555_CR43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2174\/092986709787909604","volume":"16","author":"A Musenga","year":"2009","unstructured":"Musenga A, Saracino MA, Sani G, Raggi MA. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Curr Med Chem. 2009;16:1463\u201381.","journal-title":"Curr Med Chem."},{"issue":"4","key":"555_CR44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","volume":"12","author":"E Spina","year":"2016","unstructured":"Spina E, Hiemke C, de Leon J. Assessing\u00a0drug\u00a0-drug\u00a0interactions\u00a0through\u00a0therapeutic\u00a0drug monitoring when\u00a0administering\u00a0oral\u00a0second-generation\u00a0antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407\u201322.","journal-title":"Expert Opin Drug Metab Toxicol."}],"updated-by":[{"DOI":"10.1007\/s40261-017-0567-3","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0555-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T04:56:38Z","timestamp":1659243398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0555-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0555-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}